ABEO Abeona Therapeutics Inc.

SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Abeona Therapeutics Inc. and Advises Investors with Losses to Contact the Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Abeona Therapeutics Inc. (“Abeona” or the “Company”) (Nasdaq: ABEO) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Abeona shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].

Mako Research published a report on SeekingAlpha.com finding that “ABEO science is demonstrably unviable with numerous irrefutable flaws that will lead to failure.” According to the report, Steven H. Rouhandeh, the Company’s Executive Chairman and Principal Executive Officer, was once a managing director at D. Blech & Co., a brokerage firm that was the subject of SEC investigations during the 1990s and was subject to a securities class action suit that resulted in a $15 million investor settlement due to allegations that the firm manipulated the price of some biotech stocks through transactions that artificially inflated the market price of the stocks to keep the firm’s interest in these stocks afloat. When this information was revealed to the public, the value of Abeona fell, causing investors severe harm.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [email protected].

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
19/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abeona Therapeutics Inc.

 PRESS RELEASE

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025...

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 97...

 PRESS RELEASE

Abeona Therapeutics® Announces New Employee Inducement Grants Under Na...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On January 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, i...

 PRESS RELEASE

Abeona Therapeutics® Announces New Employee Inducement Grants Under Na...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On December 30, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awar...

 PRESS RELEASE

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief...

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company’s corporate strategy and business development functions, as well as drive operating efficiency for the Company. “Mohamad brings a wealth of experience in strategic planning and business development,” said Vish Seshadri, Chief Executive Officer of Abeo...

 PRESS RELEASE

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVA...

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN, a first-of-its-kind, FDA-approved autologous, gene therapy is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch